US Patent 9,603,814: Scope, Claims, Expiration, Orange Book Status, and Fenfluramine Patent Landscape

US Patent No. 9,603,814 protects a multi-drug treatment method for Dravet syndrome that combines fenfluramine with stiripentol, valproate, and clobazam. The patent was issued on April 18, 2017, and claims priority to a December 12, 2014 filing. Its scheduled patent-term expiration is December 12, 2034, subject to any applicable patent-term adjustment or disclaimer. The principal commercial relevance is to Fintepla, the fenfluramine product marketed by Jazz Pharmaceuticals.

The independent claim is narrower than a general fenfluramine treatment claim. It requires all four agents, a patient diagnosed with Dravet syndrome, administration of fenfluramine at an effective dose, and stimulation of at least one specified serotonin receptor class. Generic or competing products that omit stiripentol, valproate, or clobazam would not directly practice the claim as written.

What does US Patent 9,603,814 cover?

US 9,603,814 covers a method of treating a patient diagnosed with Dravet syndrome by administering four components:

Fenfluramine or a pharmaceutically acceptable salt.
Stiripentol or a pharmaceutically acceptable salt.
Valproate or a pharmaceutically acceptable salt.
Clobazam or a pharmaceutically acceptable salt.

The claim also requires that fenfluramine stimulate one or more serotonin, or 5-HT, receptor classes selected from 5-HT1 through 5-HT7. The patent is therefore directed to a specific pharmacologic combination rather than to fenfluramine monotherapy.

Element	Claim requirement	Commercial significance
Disease	Patient diagnosed with Dravet syndrome	Excludes patients treated for unrelated epilepsies
Active ingredient 1	Fenfluramine or salt	Core Fintepla active ingredient
Active ingredient 2	Stiripentol or salt	Required combination component
Active ingredient 3	Valproate or salt	Required combination component
Active ingredient 4	Clobazam or salt	Required combination component
Mechanism	Stimulation of one or more listed 5-HT receptors	Functional limitation tied to fenfluramine activity
Dose limitation	Claim 2 specifies 0.5 mg/kg/day to 0.01 mg/kg/day	Dose-dependent dependent claim

How should claim 1 of US 9,603,814 be construed?

Claim 1 is a method claim with several cumulative limitations. Each limitation must be satisfied for literal infringement.

The claim requires a diagnosed Dravet syndrome patient

The patient must be diagnosed with Dravet syndrome. The claim does not cover every patient with treatment-resistant epilepsy, Lennox-Gastaut syndrome, or another seizure disorder. A treatment regimen administered to a patient without a Dravet syndrome diagnosis would not satisfy this express limitation.

The term “diagnosed with Dravet syndrome” is commercially important because FDA-approved fenfluramine use extends beyond Dravet syndrome. Fintepla received a later approval for seizures associated with Lennox-Gastaut syndrome, but that indication does not automatically fall within claim 1 of the ’814 patent. The claim is diagnosis-specific.

The claim requires all four drugs

The word “and” links fenfluramine, stiripentol, valproate, and clobazam. A regimen containing fenfluramine and clobazam but excluding stiripentol would not literally meet claim 1. The same applies to regimens that use fenfluramine alone or with valproate alone.

This limitation reduces the claim’s reach against broad fenfluramine substitution. It also creates a potential non-infringement pathway for a product label that promotes fenfluramine without requiring, recommending, or instructing use with each of the three other agents.

The claim covers pharmaceutically acceptable salts of each agent. A defendant cannot generally avoid the claim merely by using a conventional salt form instead of the free compound.

The claim covers one or more 5-HT receptor classes

The receptor limitation is broad in category. It reaches stimulation of one or more receptor classes among 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7.

Because the claim uses “one or more,” it does not require stimulation of all seven receptor classes. Evidence that fenfluramine stimulates only one listed class may be sufficient for this element, depending on the applicable claim-construction and proof standards.

The functional phrase “whereby the 5-HT receptors are stimulated” may be treated as a result or intended-use limitation if receptor stimulation necessarily follows from the claimed administration. Its legal effect would depend on the intrinsic patent record, prosecution history, expert evidence, and the forum’s claim-construction analysis.

What does claim 2 add?

Claim 2 depends on claim 1 and adds a fenfluramine dose limitation stated as “0.5 mg/kg/day to 0.01 mg/kg/day.”

The endpoints are written in descending order. In ordinary technical usage, the language would likely be read as a range spanning 0.01 to 0.5 mg/kg/day, but the exact construction could become material in litigation. Claim 2 therefore creates a narrower dose-specific position while inheriting every limitation of claim 1.

Claim	Scope	Practical effect
Claim 1	Four-drug Dravet syndrome regimen with receptor stimulation	Broadest asserted method claim in the provided claims
Claim 2	Claim 1 plus 0.01-0.5 mg/kg/day fenfluramine range	Narrower dose-based claim

The FDA-approved Fintepla dosing schedule can overlap this range. For patients receiving stiripentol, the FDA label specifies lower fenfluramine dosing than for patients not receiving stiripentol. That overlap gives claim 2 potential relevance to labeled combination use, although infringement depends on the full regimen and the precise facts of use. [2]

When does US Patent 9,603,814 expire?

The patent’s listed expiration date is December 12, 2034, based on the December 12, 2014 priority and filing chronology shown in the patent record. The patent term may be affected by patent-term adjustment, terminal disclaimer, or other statutory calculation. The effective enforceable date should be confirmed against the USPTO patent record and any Orange Book listing. [1]

Event	Date
Earliest claimed priority	December 12, 2014
Patent issued	April 18, 2017
Scheduled expiration	December 12, 2034
FDA Fintepla approval for Dravet syndrome	June 25, 2020
FDA Fintepla approval for Lennox-Gastaut syndrome	June 25, 2022

Patent expiration is distinct from FDA regulatory exclusivity. A patent can remain enforceable after orphan-drug exclusivity expires, and a product can retain orphan exclusivity even where a particular patent claim does not cover the approved use.

What is the FDA and Orange Book status of the patent?

Fintepla, containing fenfluramine hydrochloride, was approved by FDA in June 2020 for seizures associated with Dravet syndrome in patients two years of age and older. FDA later approved Fintepla for seizures associated with Lennox-Gastaut syndrome. [2,3]

Fintepla is subject to a risk evaluation and mitigation strategy because of fenfluramine-associated cardiac valvulopathy and pulmonary arterial hypertension risks. The FDA labeling requires echocardiographic monitoring before treatment, during treatment, and after discontinuation. [2]

The relevant regulatory distinctions are:

The ’814 patent is a method-of-treatment patent.
FDA approval is indication-specific and does not determine infringement.
Orange Book listing is separate from patent validity.
An ANDA applicant may challenge an Orange Book-listed patent through a Paragraph IV certification.
If the NDA holder receives notice of a Paragraph IV certification and files suit within the statutory period, an automatic 30-month stay may apply under the Hatch-Waxman Act. [4]

A complete Orange Book assessment must distinguish the ’814 patent from other patents listed for Fintepla, including possible later formulation, dosing, or method-of-use patents. The ’814 patent should not be treated as the entire Fintepla estate.

What exclusivity protects Fintepla independently of the patent?

Fenfluramine was not a new active ingredient in the broad historical sense, because fenfluramine had previously been marketed outside the current Dravet syndrome indication. The commercial protection for Fintepla therefore relies heavily on orphan-drug exclusivity, patent rights, FDA labeling, and the practical complexity of the treatment regimen.

FDA granted Fintepla orphan-drug exclusivity for Dravet syndrome following the 2020 approval. The seven-year period is generally associated with the June 25, 2020 approval date and would extend to approximately June 25, 2027 for the protected orphan indication, subject to the scope of the designation and applicable FDA rules. The later Lennox-Gastaut approval may carry separate indication-specific orphan protection. [3,5]

Protection	General relevance
Patent protection	Potentially extends into December 2034
Orphan-drug exclusivity	Blocks approval of the same drug for the protected orphan indication during the applicable period
New clinical investigation exclusivity	May apply to qualifying approval-supporting studies, depending on FDA designation
REMS	Creates regulatory and operational barriers but is not market exclusivity
Trade secrets and know-how	May protect manufacturing, quality control, and distribution systems

How strong is the patent estate for fenfluramine?

The ’814 patent has meaningful commercial value but a narrower claim profile than a patent covering fenfluramine itself.

Strengths

The claim combines several features of the approved Dravet treatment environment:

A defined rare disease.
Fenfluramine administration.
Co-administration with three established antiseizure medicines.
A receptor-based pharmacologic limitation.
A dose range that may overlap clinical use.

The disease limitation can support a use-specific patent position. The combination limitation can also make a label-based challenge more difficult if the proposed generic label instructs use alongside stiripentol, valproate, and clobazam.

Vulnerabilities

The claim has several potential pressure points:

A generic label may omit one or more required co-medications.
Prescribers may use fenfluramine outside the claimed four-drug combination.
The receptor limitation may create questions concerning proof of receptor stimulation.
The claim 2 dose range is drafted in reversed numerical order.
Prior-art challenges could target fenfluramine’s known pharmacology, antiseizure combinations, or treatment methods.
The patent does not, based on the supplied claims, cover every formulation, manufacturing process, dosage schedule, or indication.

Patent validity would depend on written description, enablement, novelty, obviousness, indefiniteness, and prosecution-history issues. The claim text alone does not establish validity or enforceability.

Which companies are challenging Fintepla exclusivity?

The principal commercial threat is expected to come from generic manufacturers pursuing an ANDA for fenfluramine hydrochloride. Because Fintepla is a small-molecule product, the relevant pathway is an ANDA rather than a biosimilar application.

A generic applicant could pursue one or more strategies:

Paragraph III certification, accepting delayed launch until patent expiration.
Paragraph IV certification, alleging that a listed patent is invalid, unenforceable, or not infringed.
A label designed to avoid one or more claimed method steps.
A restricted indication or “skinny label,” where legally available.
Post-expiration entry after December 2034.

No biosimilar pathway applies to fenfluramine. Biosimilar risk is therefore not a relevant category for this product.

Publicly reported litigation should be assessed patent by patent and defendant by defendant. The existence of a Paragraph IV certification does not establish invalidity, non-infringement, or an imminent launch. A filed patent case also does not establish that a generic will enter before patent expiration.

What patent litigation affects US 9,603,814?

The patent text does not resolve litigation status. The operative questions are whether the patent is listed for the relevant Fintepla indication, whether an ANDA applicant has served a Paragraph IV notice, whether the NDA holder filed within the statutory period, and whether a court has issued a judgment or settlement.

For business planning, the key litigation checkpoints are:

Checkpoint	Commercial implication
Orange Book listing	Enables statutory patent certification process
Paragraph IV notice	Signals an ANDA challenge
ANDA litigation filing	May trigger a 30-month stay
Preliminary injunction or trial judgment	Can alter launch timing
Settlement agreement	May establish an agreed generic-entry date
Patent expiry or disclaimer	Determines remaining exclusionary term

No conclusion about early generic entry should be drawn solely from the existence of the ’814 patent. The full Fintepla patent list, FDA listing codes, prosecution history, and any later settlement must be reviewed together.

How does the ’814 patent compare with other Fintepla protections?

Protection type	What it may cover	Relative importance
Combination method patent	Fenfluramine with stiripentol, valproate, and clobazam in Dravet syndrome	High for labeled combination use
Dose patent	Defined fenfluramine dosing	High if the generic label overlaps the dose
Formulation patent	Oral solution, excipients, concentration, or stability characteristics	Relevant to product substitution
Method-of-use patent	Dravet syndrome, Lennox-Gastaut syndrome, or other seizure populations	Relevant to indication-specific labeling
Manufacturing patent	Synthesis, purification, or active-ingredient production	Potential supply-chain barrier
Regulatory exclusivity	Orphan indications and qualifying clinical data	Independent of patent validity

The ’814 claim set supplied here does not itself establish protection for a particular oral solution, container, concentration, excipient system, manufacturing process, or Lennox-Gastaut indication.

What are the generic launch scenarios?

Launch after patent expiration

This is the lowest-risk pathway. A generic manufacturer waits until the relevant patents and regulatory exclusivities no longer block approval or commercial launch.

Paragraph IV launch

A generic applicant may allege that the ’814 patent is invalid or not infringed. If the NDA holder sues, litigation can delay approval or commercial entry. The generic may still launch at risk before final judgment, exposing it to damages and injunctive relief.

Design-around launch

A generic may seek a label that does not instruct use with all three of stiripentol, valproate, and clobazam. The success of that strategy would depend on the proposed labeling, physician behavior, induced-infringement theories, and the scope of other Fintepla patents.

Product substitution without full method overlap

A product could avoid literal infringement of claim 1 if it is used for Lennox-Gastaut syndrome or another condition, or if the labeled regimen does not require all four agents. Other patents could still constrain that launch.

Key Takeaways

US 9,603,814 is a Dravet syndrome combination-treatment patent.
Claim 1 requires fenfluramine, stiripentol, valproate, and clobazam in the same treatment method.
The claim does not cover fenfluramine monotherapy on its face.
Claim 2 adds a fenfluramine dose range stated as 0.5 to 0.01 mg/kg/day.
The listed patent expiration is December 12, 2034.
Fintepla received FDA approval for Dravet syndrome in 2020 and Lennox-Gastaut syndrome in 2022.
Orphan-drug exclusivity and patent protection are separate rights.
Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
The patent’s commercial strength is highest against a labeled regimen that instructs use of fenfluramine with all three specified antiseizure drugs.
The full Fintepla estate must be reviewed for formulation, dosing, method-of-use, manufacturing, and later-issued patent claims.

FAQs

Does US 9,603,814 cover Fintepla used alone?

No. The supplied claim requires simultaneous administration of stiripentol, valproate, and clobazam with fenfluramine. A monotherapy regimen does not satisfy the express combination limitations of claim 1.

Does the patent cover fenfluramine for Lennox-Gastaut syndrome?

Not based on the supplied claims. Claim 1 requires a patient diagnosed with Dravet syndrome. The later FDA approval for Lennox-Gastaut syndrome does not expand the claim’s disease limitation.

Can a generic avoid the patent by using a different fenfluramine salt?

Not necessarily. Claim 1 expressly covers fenfluramine and pharmaceutically acceptable salts. A conventional salt substitution would not, by itself, avoid the claim.

Is a Paragraph IV certification proof that the patent is invalid?

No. A Paragraph IV certification is an applicant’s legal position that a listed patent is invalid, unenforceable, or not infringed. The issue is resolved through litigation, settlement, or later court proceedings.

Does the patent protect the manufacture of fenfluramine?

The supplied claims do not claim a manufacturing process. They claim a method of administering a treatment combination. Separate process or composition patents would be needed to establish manufacturing protection.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,603,814, methods of treating Dravet syndrome.
U.S. Food and Drug Administration. (2023). Fintepla (fenfluramine hydrochloride) prescribing information.
U.S. Food and Drug Administration. (2020). FDA approves new therapy for seizures associated with Dravet syndrome.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014261329	⤷ Start Trial
Australia	2019203448	⤷ Start Trial
Australia	2019203832	⤷ Start Trial
Australia	2020267264	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,603,814

Which drugs does patent 9,603,814 protect, and when does it expire?

Summary for Patent: 9,603,814